nivolumab

News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me

nivolumab
May 21, 2025, 19:10 | Insight
Samuel Hume: Top 5 advances in medicine this week
Samuel Hume, Fellow at The Foulkes Foundation and pursuing PhD in the University of Oxford’s…
May 21, 2025, 16:57 | Science
Guru Sonpavde: CheckMate 901 Trial Data on First-Line Nivolumab in LN-Only Metastatic Urothelial Carcinoma
Guru Sonpavde, GU Oncology and Phase I Clinical Trials Director, Chair of Bladder Cancer Research…
May 10, 2025, 17:01 | Drugs
FDA approved Bristol Myers Squibb’s Opdivo + Yervoy for first-line treatment of MSI-H/dMMR metastatic colorectal cancer
Fight Colorectal Cancer shared a post on LinkedIn: "Congratulations to Bristol Myers Squibb on the…
May 5, 2025, 07:08 | Oncolibrary,Science
Top clinical trials at ESTRO 2025: Nivolumab plus ChemoRT in Patients with Muscle-Invasive Bladder Cancel. Final Results of a Phase Il Study by the HGUCG
Bladder preservation therapy, consisting of maximal transurethral resection (TURBT) followed by chemoradiotherapy (CRT), has emerged…
Apr 11, 2025, 22:39 | Insight
Michael Sapienza: FDA Approves Nivolumab/Ipilimumab for Colorectal Cancer
Michael Sapienza, Chief Executive Officer at Colorectal Cancer Alliance, shared the following insightful post on…
Apr 4, 2025, 09:15 | Blog
Tian Zhang: Best practices for second line treatment in Metastatic Urothelial Carcinoma
Tian Zhang, Associate Professor in the Department of Internal Medicine at UT Southwestern Medical Center, shared…
Apr 3, 2025, 08:53 | Drugs
Tian Zhang and Petros Grivas discussed best practices for Metastatic Urothelial Carcinoma Therapy
Tian Zhang, Associate Director of Clinical Research at Simmons Comprehensive Cancer Center and Director of…
Apr 1, 2025, 09:47 | Science
Giulia Claire Giudice: Strategies for RCC patients progressing on ICIs
Giulia Claire Giudice, Medical Doctor at University Hospital of Parma, shared an article on X: "Newly…
Mar 30, 2025, 14:01 | Cancer Types
Melanoma (Skin Cancer): Symptoms, Causes, Stages, Diagnosis and Treatment
Skin cancer is one of the most common forms of cancer worldwide, with melanoma being…
Mar 28, 2025, 14:09 | Oncolibrary
Ocular Side Effects Of Immune Checkpoint Inhibitors
Immune checkpoint inhibitors (ICIs) are a type of immunotherapy that enhances the body’s immune response…
Mar 26, 2025, 14:26 | Science
Yüksel Ürün: Revolution in Metastatic Melanoma
Yüksel Ürün, Medical Oncology professor at Ankara University School of Medicine, shared an article by…
Mar 2, 2025, 13:57 | Science
Mohammad Jad Moussa: Nivolumab plus ipilimumab in metastatic variant histology renal cell carcinoma
Mohammad Jad Moussa, Oncology Fellow at MD Anderson Cancer Center, shared a post on X…
Feb 26, 2025, 16:33 | Blog
Iván R. González: Neoadjuvant Nivolumab Plus Ipilimumab versus Chemotherapy in Patients with Resectable NSCLC
Iván R. González, Medical Oncologist at the Comprehensive Cancer Center, Hospital Ángeles Puebla, shared on X:…
Feb 25, 2025, 07:58 | Science
Efficacy and safety of nivo/ipi in patients with metastatic vhRCC by Mohammad Jad Moussa et al.
A paper by Mohammad Jad Moussa et al. was published in Journal for ImmunoTherapy of…
Feb 24, 2025, 07:28 | Blog
Amanda Impellizzeri: Louisiana Oncology Society's first-ever workshop on tackling insurance denials in NOLA
Amanda Impellizzeri, Executive Director of 3 Oncology State Societies and Leadership Relations Manager at The…
Feb 21, 2025, 14:08 | Science
Survival improvement of patients with melanoma brain or leptomeningeal metastases in Denmark - CCIT-DK
CCIT-DK - National Center for Cancer Immune Therapy of Denmark shared an article by Sidsel…
Feb 19, 2025, 10:01 | Drugs
Opdivo (Nivolumab): Uses in Cancer, Side Effects, Dosages, Expectations, and More
Opdivo (nivolumab) is a monoclonal antibody and immunotherapy drug which is a revolutionary approach that harnesses…
Feb 5, 2025, 20:31 | Science
Marco Donia on managing melanoma brain metastases after progression on anti-PD-1 therapy
Marco Donia, Clinical Research Associate Professor at the University of Copenhagen, shared a post on…
Feb 2, 2025, 18:11 | Blog
Vivek Subbiah: Delighted to host the latest episode of the JAMA Oncology podcast
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a…
Jan 28, 2025, 17:20 | Insight
Pashtoon Kasi: Very intriguing to see differences of single agent PD1 vs combination with CTLA4
Pashtoon Kasi, Medical Director of GI Medical Oncology at City of Hope, shared a post…
Jan 28, 2025, 06:19 | Science
Yakup Ergün: The New Standard of Care in MSI-H CRC-Nivolumab + Ipilimumab
Yakup Ergün, Medical Oncologist at Antalya City Hospital, shared a recent article by Thierry Andre…
Jan 26, 2025, 15:29 | Science
Pallawi Torka: Phase II Trial of Frontline Therapy for Older Adults with Hodgkin Lymphoma
Pallawi Torka, Assistant Attending at Memorial Sloan Kettering Cancer Center, shared a post on X…
Jan 25, 2025, 03:46 | Insight
Estela Rodriguez: Using nivolumab plus ipilimumab as a treatment to patients with metastatic NSCLC
Estela Rodriguez, Associate Director of Community Outreach and Co-Lead of the Thoracic Site Disease Group…
Jan 20, 2025, 16:30 | Insight
Susanna F. Greer: Outsmarting Kidney Cancer - A New Triple Therapy Approach
Susanna F. Greer, Chief Scientific Officer at The V Foundation for Cancer Research and Leading…
Jan 16, 2025, 16:03 | Science
Estela Rodriguez: Updated analysis of CM816
Estela Rodriguez, Associate Director of Community Outreach and Co-Lead of the Thoracic Site Disease Group…
Jan 13, 2025, 04:50 | Insight
Hidehito Horinouchi: Potential long-term clinical benefit from CheckMate 816
Hidehito Horinouchi, Assistant Chief of the National Cancer Center Hospital, shared a post on X…
Jan 11, 2025, 16:54 | Insight
Patrick Forde: Neoadjuvant Nivolumab Plus Ipilimumab Versus Chemotherapy in Resectable Lung Cancer
Patrick Forde, Professor at Johns Hopkins University, shared a post on X about a recent…
Jan 7, 2025, 18:04 | Insight
Stephen Liu: What is the best way to assess response of brain metastases to systemic treatment?
Stephen Liu, Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared a post on X:…
Jan 7, 2025, 14:28 | Science
Valuable insights from a new article on Unresectable Stage IIIA/IIIB NSCLC - IU Simon Comprehensive Cancer Center
IU Simon Comprehensive Cancer Center shared a post on LinkedIn about a recent paper by…
Jan 7, 2025, 14:24 | Insight
Mark Lythgoe: FDA Approves Subcutaneous Nivolumab and Atezolizumab - Boosting Immunotherapy Access
Mark Lythgoe, Clinical Research Fellow in Medical Oncology at Imperial College London, shared a post…
Jan 3, 2025, 12:40 | Insight
Senthil Kumar: First-Line Therapy in RCC, Expanding Choices in a New Era
Senthil Kumar, Medical Oncologist at Red Hills, Chennai, posted on X: “First-Line Therapy in RCC:…
Jan 2, 2025, 15:51 | Insight
Stephen V Liu: The FDA Approved CheckMate 77T regimen for resectable NSCLC
Stephen V Liu, Associate Professor of Medicine at Georgetown University, Director of Thoracic Oncology and…
Jan 2, 2025, 15:20 | Blog
Elvina Almuradova: A New Era in Cancer Treatment - FDA Approves Subcutaneous Nivolumab
Elvina Almuradova, Associate Professor of Oncology at IEO Istituto Europeo di Oncologia, shared a post…
Dec 31, 2024, 09:49 | Insight
Mark Lythgoe: Subcutaneous nivolumab approved by FDA Oncology across all indications
Mark Lythgoe, Clinical Research Fellow in Medical Oncology at Imperial College London, shared on X:…
Dec 30, 2024, 00:53 | Science
Marco Donia about the FDA approved nivolumab across solid tumors
Marco Donia, Senior Consultant at the University of Copenhagen Herlev Hospital, shared a recent article…
Dec 29, 2024, 10:19 | Insight
Pashtoon Kasi: All about efficiency
Pashtoon Kasi, Medical Director of GI Medical Oncology at City of Hope, Orange County, shared…
Dec 29, 2024, 10:07 | Blog
Oncology Brothers: 14 new drugs/indications in Lung Cancer by FDA in 2024
Oncology Brothers posted on X: "2024 approvals: Summary of 14 new drugs/indications in Lung Cancer…
Dec 28, 2024, 18:09 | Drugs
Rami Manochakian: FDA approved subcutaneous Nivolumab for Solid Tumors
  Rami Manochakian, Thoracic medical oncologist at Mayo Clinic, shared a post on X: "U.S FDA…
Dec 28, 2024, 13:49 | Insight
Timothée Olivier: What is the best 1st line immunotherapy regimen for patients with advanced/meta melanoma?
Timothée Olivier, Medical oncologist at the Oncology Division of Geneva University, shared a recent article…
Dec 28, 2024, 13:45 | Insight
FDA Approved Subcutaneous Nivolumab in Advanced or Metastatic Solid Tumors
The FDA has approved nivolumab and hyaluronidase-nvhy (Opdivo Qvantig; subcutaneous nivolumab) for subcutaneous injection for…
Dec 28, 2024, 09:40 | Science
5 papers about Lung Cancer suggested by Stephen Liu
Stephen Liu, Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared a few must-reads papers…
Dec 26, 2024, 15:10 | Insight
Eliminating cancer with nivolumab and the chemotherapy regimen AVD - NCI
National Cancer Institute (NCI) shared a post on LinkedIn: "In a large clinical trial, treatment…
Dec 22, 2024, 10:44 | Science
5 papers about Lung Cancer suggested by Stephen Liu
Stephen Liu, Associate Professor at Georgetown Lombardi Comprehensive Cancer Center, shared a few must-reads papers…
Dec 22, 2024, 05:22 | Insight
Camilla Perucchini: I have officially graduated with a Master of Science in Biotechnology curriculum
Camilla Perucchini, Clinical Study Coordinator at IFO - Istituto Nazionale Tumori Regina Elena - Istituto…
Dec 16, 2024, 18:57 | Insight
Next generation sequencing-based MSI scoring predict benefit in dMMR tumors treated with nivolumab
María Natalia Gandur Quiroga shared a post on X: "NGS-Based MSI Scoring Predicts Nivolumab Benefit…
Dec 16, 2024, 08:08 | Insight
Ben Westphalen: New biomarkers in non-colorectal dMMR tumors highlighted in NCI MATCH
Ben Westphalen, Chair of Translational Research and Precision Medicine Working Group at ESMO, shared some…
Dec 11, 2024, 17:56 | Insight
Aakash Desai: A Year of Remarkable Progress in Lung Cancer and Mesothelioma Treatments
Aakash Desai, Assistant Professor at UAB O’Neal Comprehensive Cancer Center, posted on LinkedIn: “A Year…
Dec 8, 2024, 05:13 | Insight
Angela Lamarca: Update form CHECKMATE-9DW trial in HCC - Asian population with Ipilimumab and nivolumab
Angela Lamarca, HPB and NET Medical Oncologist at Jimenez Diaz Foundation, shared a post on…
Dec 7, 2024, 01:42 | Blog
Toni Choueiri: Excited to share the results of FRACTION-RCC
Toni Choueiri, the Director of the Lank Center for Genitourinary (GU) Oncology at Dana-Farber Cancer…
Nov 30, 2024, 18:30 | Insight
Young Kwang Chae: Nivolumab/Ipilimumab can be effective in select non-epithelial ovarian cancer
Young Kwang Chae, Associate Professor of Medicine, medical oncologist, and physician-scientist at Northwestern University’s Feinberg…
Nov 30, 2024, 16:17 | Insight
Vivek Subbiah: The development of immunotherapy in MSI-H and D-MMR cancers by Thierry Andre et al.
Vivek Subbiah, Chief of Early-Phase Drug Development at the Sarah Cannon Research Institute, shared a…
Nov 16, 2024, 15:57 | Insight
Neoadjuvant nivolumab and relatlimab in locally advanced MSI CRC
Arndt Vogel, Managing Senior Consultant and a Professor in the Department of Gastroenterology, Hepatology, and…
Nov 11, 2024, 17:49 | Blog
Erman Akkus: Nivolumab-ipilimumab vs SOC for non-clear cell RCC
Erman Akkus, Medical Oncology fellow at the Ankara University, shared a post on X: "Nivolumab-ipilimumab…
Nov 10, 2024, 00:33 | Insight
Marwan Fakih: Updated RIN results in MSS chemo-refractory non-liver metastatic colorectal cancer
Marwan Fakih, Associate Director for Clinical Sciences at City of Hope, shared a post on…
Nov 8, 2024, 19:15 | Insight
Ipilimumab with or without Nivolumab in Classic Hodgkin Lymphoma with PD after CPI at ASH24
Ajay Major, Assistant Professor of Medicine at the University of Colorado School of Medicine, shared…
Nov 2, 2024, 15:51 | Immune Oncology
Immunotherapy for Metastatic Colon Cancer: Types, Success Rate, Side Effects & More
Immunotherapy has emerged as a promising treatment option for colon cancer, particularly for patients with…
Oct 29, 2024, 21:00 | Positive
Steven O'Day: At the Forefront of Immunotherapy
Dr. Steven O'Day, an immunotherapy pioneer and medical oncologist, is the Chief Medical Officer at…
Oct 20, 2024, 17:47 | Drugs
Stephen V Liu: Long-term survival with nivolumab and ipilimumab in advanced NSCLC
Stephen V Liu shared on X: "Long-term survival (median f/u 73.7m) with nivolumab and ipilimumab…
Oct 18, 2024, 19:52 | Blog
Mariano Provencio: Perioperative chemotherapy and nivolumab in NSCLC
Mariano Provencio, Medical Oncology Chair at University Hospital Puerta de Hierro, shared on X: ''With…
Oct 16, 2024, 17:00 | Insight
Biagio Ricciuti: 5-year update from the NADIM trial
Biagio Ricciuti shared a post on X about a recent paper by Mariano Provencio et…
Oct 11, 2024, 14:37 | Insight
U.S. FDA approved nivolumab with platinum-doublet chemotherapy
Toni Choueiri shared a post on X: "JUST IN: US_FDA approved nivolumab with platinum-doublet chemotherapy…
Oct 8, 2024, 15:29 | Insight
Jarushka Naidoo: Long-Term Survival Outcomes With First-Line Nivolumab Plus Ipilimumab in NSCLC
Jarushka Naidoo shared a post on X: “Long-Term Outcomes 1L Ipilimumab/Nivolumab/-Chemo v Chemo in PDL1<1%…
Oct 5, 2024, 23:43 | Insight
MD Anderson Research Highlights for the 2024 World Conference on Lung Cancer
The University of Texas MD Anderson Cancer Center’s Research Highlights provides a glimpse into recent…
Oct 2, 2024, 15:14 | Blog
Suraj Samtani: Real-World Study of first Line Nivolumab plus Ipilimumab in Unresectable Pleural Mesothelioma
Suraj Samtani, Medical Oncologist at Harvard Medical School, shared a post on X, about recent…
Sep 27, 2024, 16:31 | Insight
Immunotherapy for aggressive breast cancer appears to be effective even without chemotherapy - The Netherlands Cancer Institute
The Netherlands Cancer Institute posted on LinkedIn: "Immunotherapy as a treatment for an aggressive form of…
Sep 26, 2024, 14:05 | Blog
Stephen V Liu: Real-world study of first-line nivolumab and ipilimumab for pleural mesothelioma
Stephen V Liu shared a post on X, about recent paper published in Clinical Lung…
Sep 21, 2024, 15:21 | Insight
Ulrike Harjes: Promising response rates with Nivolumab in TNBC patients
Ulrike Harjes, Senior Editor at Nature Medicine, posted the following on X: “Out now in Nature…
Sep 21, 2024, 13:13 | Blog
Florian Lordick: Niche2 data presented by Myriam Chalabi
Florian Lordick, Professor of Medicine at University of Leipzig and Director of the Comprehensive Cancer…
Sep 21, 2024, 09:03 | Blog
Neoadjuvant nivolumab with or without ipilimumab in early stage TNBC
Top Biomedical Science shared a post on X, about recent paper published in Nature Medicine:…
Sep 17, 2024, 16:15 | Blog
Median overall survival in melanoma with nivolumab plus ipilimumab presented at ESMO24 - NEJM
NEJM posted the following on X: “Presented at ESMO24: Among patients with advanced melanoma, median…
Sep 15, 2024, 23:34 | Insight
Insights from ESMO24 Day 2
The ESMO Congress 2024 is ongoing in Barcelona, from September 13 to 17, 2024, at…
Sep 12, 2024, 14:42 | Insight
Colon Cancer Treatment: NICHE-2 Validates Immunotherapy
Maria Babak shared a post by The Babak Lab on LinkedIn: “ This research highlights…
Sep 7, 2024, 08:54 | Insight
Ipilimumab or Relatlimab Plus Nivolumab in Advanced Melanoma
Marco Donia shared a post on LinkedIn: "Ipilimumab Plus Nivolumab or Relatlimab Plus Nivolumab in…
Sep 5, 2024, 18:09 | Blog
How biomarkers can predict patients' responses to ICI treatments - CRI
CRI (Cancer Research Institute) shared a post on LinkedIn: ''Led by CRI Scientific Advisory Council…
Sep 2, 2024, 13:49 | Insight
Article of the day, September 2nd, suggested by the Immune Oncology Research Institute
Immune Oncology Research Institute shared a post on LinkedIn: “Article of the day! Suggest by the Immune…
Sep 2, 2024, 08:35 | Insight
Shilpa Gupta: Novel approach of intermittent IO in mRCC
Shilpa Gupta shared a post on X by María Natalia Gandur Quiroga about a recent…
Aug 29, 2024, 11:25 | Insight
Article of the day, August 29th, suggested by the Immune Oncology Research Institute
Immune Oncology Research Institute shared a post on LinkedIn: “Article of the day! Suggest by the Immune…
Aug 26, 2024, 04:06 | Blog
Article of the Day, August 25th, suggested by IMMONC
Immune Oncology Research Institute made the following post on LinkedIn: “Article of the day suggested…
Aug 20, 2024, 10:18 | Blog
Key points by Oncology Brothers on Durva+Chemo approval based off AEGEAN trial
H. Jack West, Vice President of Clinical Development at Summit Therapeutics, Inc, shared a post…
Aug 10, 2024, 13:59 | Insight
New hope in treating advanced grade 3 Neuroendocrine Neoplasms - Garcia-Carbonero's Lab
Garcia-Carbonero's Lab shared a post on X: “New hope in treating advanced grade 3 Neuroendocrine…
Aug 9, 2024, 05:53 | Blog
Nivolumab with and without ipilimumab in solid tumors of high mutational burden - Journal for ImmunoTherapy of Cancer
Journal for ImmunoTherapy of Cancer shared a post on X, about recent paper published in…
Aug 7, 2024, 03:03 | Insight
Extended 8-year follow-up results of efficacy and safety from the phase III CheckMate 214 trial
Daniel Castellano, Medical Oncologist at University Hospital October 12, shared on X: “Nivolumab plus ipilimumab…
Aug 7, 2024, 01:22 | Insight
8 years of follow-up in the CheckMate 214 trial
Yüksel Ürün shared a paper by Nizar M. Tannir et al. on X: "Nivolumab +…
Aug 6, 2024, 14:55 | Blog
Stephen Liu: Discussion on the emergence of immunotherapy in lung cancer
Stephen Liu shared on X: "Highlighting one of my favorite episodes of the IASLC podcast,…
Aug 2, 2024, 12:10 | Blog
Breaking Science in Gastrointestinal Cancers with Francesco Sclafani - ESMO
ESMO (European Society for Medical Oncology) shared a post on LinkedIn: ''For ESMO members: Breaking…
Aug 2, 2024, 11:14 | Insight
Razelle Kurzrock: Our newest DART study
Razelle Kurzrock shared a post by the Journal for ImmunoTherapy of Cancer on X, adding:…
Jul 23, 2024, 10:09 | Insight
Ilya Tsimafeyeu: Intrapleural nivolumab in cancer patients with pleural effusion
Ilya Tsimafeyeu, Director at the Bureau of Cancer Re­search, shared on Facebook about a recent…
Jul 21, 2024, 08:52 | Blog
Ece Tolgay: I will be presenting a poster at the ECI2024
Ece Tolgay, Member of American Association of Immunologists, posted on X:           …
Jul 20, 2024, 18:07 | Blog
Tom Powles: More evidence that PD(L)1 re-challenge should be avoided in renal cancer
Tom Powles posted on X/Twitter: "More evidence that PD(L)1 re-challenge should be avoided in renal…
Jul 20, 2024, 10:51 | Blog
Toni Choueiri: TiNivo2 results are out
Toni Choueiri shared a post on X: ''TiNivo2 results are out - adding PD1 inhibitor…
Jul 9, 2024, 07:25 | Insight
Piotr Wysocki: Checkpoint inhibitor and TKI combinations in GU malignancies
Piotr Wysocki recently posted on LinkedIn: "A phase I study (Apolo AB et al. J Clin…
Jul 5, 2024, 15:03 | Drugs
Andrea Apolo: Phase 1 study of Cabozantinib, Nivolumab, and Ipilimumab for genitourinary tumours
Andrea Apolo, Chief of Bladder Cancer Section Genitourinary Malignancies Branch Center for Cancer Research at…
Jul 5, 2024, 13:47 | Insight
Andrea Apolo: Very proud of this Clinical Trial of Cabozantinib/Nivolumab published at JCO
Shilpa Gupta shared a post by Andrea Apolo, adding: "Huge congrats Andrea Apolo, leading this…
Jul 5, 2024, 02:30 | Drugs
Ipilimumab and Nivolumab for patients with unresected advanced Hepatocellular Carcinoma - ESMO
ESMO shared on LinkedIn: "Benefits reported for the combination of ipilimumab and nivolumab further expand…
Jul 3, 2024, 00:52 | Blog
Hedyeh Ebrahimi: Intrigued by the difference in response between CBM588 and ctrl arms
Hedyeh Ebrahimi, Postdoctoral fellow at Genitourinary Cancer Research Team of City of Hope shared a…
Jul 1, 2024, 23:51 | Insight
Piotr Wysocki: Neoadjuvant therapy for renal-cell cancer patients is still in its infancy, unlike in melanoma
Piotr Wysocki recently posted on LinkedIn: "The PROSPER ECOG-ACRIN EA8143 study (published online in Lancet…
Jun 30, 2024, 14:51 | Insight
Sergio Cifuentes: Phase 2 study on neoadjuvant nivolumab + ipilimumab in dMMR colon cancer
Sergio Cifuentes, Cancer Research Project Manager at CENEIT México, shared a post on X about…
Jun 29, 2024, 14:04 | Insight
Piotr Wysocki: Combination of nivolumab and relatlimab in neoadjuvant setting in resectable NSCLC
Piotr Wysocki recently posted on LinkedIn: "Martin Schuler et al. published results of their phase 2…
Jun 29, 2024, 13:50 | Drugs
Chemotherapy with adjuvant nivolumab versus placebo for GEJ cancer
Syed A. Ahmad, Chief of Surgical Oncology at The University of Cincinnati, made the following…
Jun 29, 2024, 12:06 | Drugs
Injectable form of nivolumab vs the intravenous form against kidney cancer - NCI
National Cancer Institute (NCI) shared on X:  "In a Clinical Trial, an injectable form of…
12
All: 153 Posts: 1 - 100
Special Coverage